588 related articles for article (PubMed ID: 34442452)
1. Breast Cancer Treatments: Updates and New Challenges.
Burguin A; Diorio C; Durocher F
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442452
[TBL] [Abstract][Full Text] [Related]
2. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Breast Cancer Subtypes Among Different Ethnicities and Bangladeshi Women: Demographic, Clinicopathological, and Integrated Cancer Informatics Analysis.
Islam D; Islam MS; Dorin SI; Jesmin
Cancer Inform; 2023; 22():11769351221148584. PubMed ID: 36684416
[TBL] [Abstract][Full Text] [Related]
4. Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments.
Burguin A; Roy J; Ouellette G; Maltais R; Bherer J; Diorio C; Poirier D; Durocher F
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445276
[TBL] [Abstract][Full Text] [Related]
5. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
7. Targeting triple negative breast cancer stem cells using nanocarriers.
Dasari N; Guntuku GS; Pindiprolu SKSS
Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series.
Cosar R; Sut N; Ozen A; Tastekin E; Topaloglu S; Cicin I; Nurlu D; Ozler T; Demir S; Yıldız G; Şenödeyici E; Uzal MC
Breast Cancer (Dove Med Press); 2022; 14():259-280. PubMed ID: 36105268
[TBL] [Abstract][Full Text] [Related]
9. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
10. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
11. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.
Saha T; Lukong KE
Front Oncol; 2022; 12():856974. PubMed ID: 35392236
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
14. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
16. Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.
Das K; Paul S; Ghosh A; Gupta S; Mukherjee T; Shankar P; Sharma A; Keshava S; Chauhan SC; Kashyap VK; Parashar D
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835573
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
18. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Oualla K; El-Zawahry HM; Arun B; Reuben JM; Woodward WA; Gamal El-Din H; Lim B; Mellas N; Ueno NT; Fouad TM
Ther Adv Med Oncol; 2017 Jul; 9(7):493-511. PubMed ID: 28717401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]